Skip to main content
Premium Trial:

Request an Annual Quote

Investment Firms Begin Coverage of Complete Genomics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Four investment firms have started coverage on Complete Genomics, a day after the company reported $4.2 million in revenues for the third quarter.

Both UBS and Jefferies initiated coverage with a "Buy" rating, while Cowen and R.W. Baird gave the Mountain View, Calif.-based next-generation sequencing services firm, which went public in November, an "Outperform" rating.

Jefferies has a price target on the company's shares of $13, an 89 percent increase from Complete Genomics' $6.89 closing price on Monday. Both UBS and Baird have a target of $12 per share, while Cowen didn't place a price target on the stock.

In a research note, Quintin Lai of Baird said that Complete Genomics' focus on providing whole human genome sequencing at an affordable, all-in cost positions it uniquely in the market as researchers will be able to sequence whole humans without having to invest heavily in instrument and infrastructure expenses.

He added that its cost and 99.99 percent accuracy makes the company's service appealing to academic and pharma/biotech researchers, and the service could have clinical applications, especially in cancer research.

The National Cancer Institute and others have used its services, and, "[w]e think sequencing orders from these early adopters will help pave the way for large-scale, statistically powerful, studies to follow," Lai said.

In Tuesday afternoon trading on the Nasdaq, shares of Complete Genomics were up almost 9 percent at $7.48 per share.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.